Spanish public research foundation specializing in infectious disease epidemiology, vaccine research for ageing populations, and clinical outcome standards.
Fundación Miguel Servet is a public research foundation based in Pamplona, Spain, focused on clinical and epidemiological health research. Their work spans infectious disease surveillance (including COVID-19 and emerging viruses), vaccine development for ageing populations, liver disease therapeutics, and patient-reported outcome standards. They contribute clinical expertise and data analysis capabilities to large European health consortia, bridging primary care networks with research-grade epidemiological studies.
ISOLDA (their largest funded project at EUR 500K) focuses on improved vaccination strategies addressing immunosenescence in older adults across multiple virus types including influenza, TBEV, and MERS-CoV.
Both ISOLDA and I-MOVE-COVID-19 involve epidemiological surveillance of respiratory diseases through primary care and hospital networks across Europe.
DECISION project applies omics-based systems approaches to identify new combinatorial therapies for decompensated cirrhosis, a serious clinical endpoint.
SISAQOL-IMI focuses on establishing international standards for analyzing patient-reported outcomes, indicating a move toward clinical trial methodology and data quality.
All four of FMS's H2020 projects started between 2020 and 2021, giving a very compressed timeline for evolution analysis. Their earlier engagements emphasize infectious disease response — vaccines for emerging viruses, COVID-19 surveillance networks, and immunology of ageing. Their more recent keyword profile shifts toward chronic disease management (cirrhosis, combinatorial therapy, omics) and clinical methodology (patient-reported outcomes, data analysis), suggesting a broadening from acute infectious disease toward chronic disease research and outcome measurement standards.
FMS appears to be expanding from infectious disease expertise into chronic disease research and clinical data standardization, making them increasingly relevant for projects requiring rigorous outcome measurement.
FMS operates exclusively as a consortium participant or third party — they have never coordinated an H2020 project. Despite their small project count, they have worked with 93 unique partners across 22 countries, indicating they join large, well-connected consortia rather than leading small focused teams. This profile suggests a reliable specialist contributor that brings clinical or epidemiological capabilities to established networks without the overhead of project leadership.
Despite only four projects, FMS has built a remarkably broad network of 93 partners across 22 countries, reflecting participation in large pan-European health research consortia. Their network reach is wide rather than deep, suggesting they are well-connected through major collaborative frameworks rather than repeated bilateral partnerships.
FMS brings a distinctive combination of infectious disease epidemiology and clinical research capabilities from Spain's Navarra region, home to a strong healthcare system and research ecosystem. Their dual focus on population-level surveillance (primary care networks, hospital networks) and molecular-level research (omics, immunosenescence) makes them a versatile health research partner. For consortium builders, they offer a Spanish clinical node with proven ability to integrate into large multi-country studies.
